Introduction
Cancer is the leading cause of mortality threatening human health and life. Worldwide, liver cancer ranks sixth in terms of incidence, and third in terms of mortality. 1 In the People's Republic of China, liver cancer is the second most common cancer, with an incidence of 300,000 cases each year, causing about 110,000 deaths, accounting for 45% of total liver cancer deaths worldwide. 2 Surgical treatments for early liver cancer include resection and transplantation. However, donor shortages and high expenses often lead to the death of patients prior to a liver donor. Thus, liver cancer is still a major cause of cancer death, and the 5-year survival rate of liver cancer is about 18%.
3 Twenty-two percent of patients who are unable to undergo liver resection or transplantation often died waiting for treatment. Since the currently available anticancer drugs have a low bioavailability, poor targeting properties, severe toxic effects, and can significantly suppress immune functions. Therefore, finding a drug with high efficiency and low side effects is necessary for treating liver cancer. In recent years, liver-targeting drug delivery systems have become a hotspot in strategies for liver cancer therapy. These systems play an essential role in cancer therapy since they can specifically deliver drugs to liver lesions and not to normal liver tissues, thus allowing decreasing dosage and dose frequency, reducing side effects, and improving treatment outcomes.
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Currently, studies about drug delivery systems mainly focus on single-targeted drug delivery systems, 6, 7 such as the chitosan (CTS)-based drug delivery system, which allows liver-targeting drug delivery using specific interactions between galactose and the asialoglycoprotein receptor (ASGP-R) expressed on liver or hepatoma cells surface. 8 Another ligand used in liver-targeting drug delivery is glycyrrhetinic acid (GA), which is enriched in liver tissues. Studies detected a large amount of GA binding sites on the surface of rat liver cells, and hepatoma cells significantly expressed more GA receptors than normal liver cells. 9 Since GA itself can inhibit hepatoma cells proliferation, GA-based livertargeted therapy could effectively suppress tumor growth, and showed satisfactory treatment outcomes. 9, 10 Nevertheless, such single-target modified nanoparticles are affected by a number of physiological or pathological factors during ligand-receptor interactions, causing failure in receptormediated functions and in targeted-therapy outcomes. For example, the density and activity of ASGP-R in patients with liver disease are reduced, thus decreasing the binding efficiency of hepatoma cells by 95%, 11 indicating that the effects of liver-targeting therapy mediated by ASGP-R only would significantly decrease or disappear. Also, since not all targeted receptors show specific overexpression in target cells, mono-ligand modified nanoparticles may have insufficient receptor binding. 12 Hence, single-targeting drug delivery systems may have limited therapeutic effects due to the limited specific recognition and binding between ligand and receptor on the target cells. In a previous study, we successfully synthesized a dual-ligand modified chitosan (GCGA) nanoparticle composed of CTS, GA, and lactobionic acid, and observed that GCGA modified nanoparticles had good liver-targeting properties, which were significantly higher than mono-ligand modified nanoparticles. 13 The thymidylate synthase inhibitor 5-fluorouracil (5-FU) has been used for half a century as a drug of choice for treating solid tumors. 14, 15 However, this drug requires intravenous injection because of low oral bioavailability and short plasma half-life (only 5 minutes in vivo). In order to reach an effective drug concentration, high doses, and continuous or repeated administration are often used in clinical practice, which in turn increase the toxicity of 5-FU. Also, 5-FU has low selectivity and high toxicity, which may lead to bone marrow suppression, mucositis, diarrhea, hair loss, and liver and kidney damage. 16 In recent years, many formulations have been tried to improve the selectivity and efficacy of 5-FU, as well as to decrease its toxicity and side effects. Researchers synthesized less toxic 5-FU prodrugs, such as fluorouridine and tegafur, and investigated their pharmacology, toxicity, metabolism, and antitumor activity. Results showed that although these prodrugs had less toxicity and higher chemotherapy index than 5-FU, they still lack tumor selectivity, and can cause adverse effects in nontarget cells and organs. 17, 18 With the use of polymer science in medicine, researchers found that when fixed on polymers, active small-molecule drugs acquired slow release and long-action characteristics, and could effectively regulate the transport and absorption of drugs in vivo. Meanwhile, since these polymer modified drugs can easily be endocytosed by tumor cells, the drugs are target released, and they have significantly fewer toxic side effects. 19 Recent studies focused on the synthesis of tumor-targeting 5-FU-coated nanoparticles to render targeting properties to 5-FU. We previously synthesized nanoparticles using galactosyl-chitosan (GC) and 5-FU. Results showed that these GC/5-FU nanoparticles had obvious targeting properties against liver cancer, and that they may regulate the distribution and metabolism of 5-FU in vivo, thereby significantly reducing the toxic side effects of 5-FU. 20 In this study, we successfully synthesized the GCGA/5-FU nanoparticle, and its characteristics were observed in vitro and in vivo. This study used GCGA/5-FU nanoparticles to treat mice with liver cancer, and results showed that GCGA/5-FU nanoparticles significantly inhibited tumor growth and attenuated the immune suppression induced by 5-FU.
Materials and methods experimental materials
Experimental materials used in this study included: CTS (.85% degree of deacetylation, Sigma-Aldrich, St Louis, MO, USA), lactobionic acid ($97% purity, Sigma-Aldrich), GA ($97% purity, Xi ' 
Preparation of GCGA/5-FU nanoparticles
The GCGA/5-FU nanoparticles were prepared using an ionic crosslinking technique. 5-FU was added into GCGA solution (dissolved in acetic acid) at a mass ratio of 1:1. An aqueous TPP solution (0.05% [w/v]) was then added to the mixture and stirred. After 50 minutes, GCGA/5-FU nanoparticles were formed by the incorporation of TPP solution at a ratio of GCGA:TPP of 5:1. The nanoparticles were centrifuged at 10,000 rpm for 30 minutes to remove NaOH and 5-FU. Purified nanoparticles were lyophilized and preserved for future use. The CTS and GA-CTS nanoparticles were prepared in the same way.
Determination of particle size and zeta potential
The cuvette containing the prepared nanoparticles suspension was placed into the sample chamber for determination of particle size and particle size distribution. A volume of 5 mL of nanoparticles suspension was injected into the pipeline for measurement of the zeta potential.
Targeting properties of GCGA/5-FU nanoparticles
We randomly divided Balb/c mice into four groups (n=5), and intravenously injected 200 µL of 5-FU solution (containing 0.371 mg 5-FU), CTS/5-FU, GA-CTS/5-FU or GCGA/5-FU solution in each group. Mice were killed 30 minutes later, and their liver, spleen, kidney, lung, muscle, and heart tissues were sampled, weighed (0.5-1.0 g), and homogenized.
A total of 0.5 mL of tissue homogenates were taken for detecting 5-FU concentration.
Distribution of GCGA/5-FU nanoparticles
We randomly divided Sprague Dawley rats into four groups (n=5). Rats in the control group were only injected with saline; rats in the CTS, GA-CTS, and GCGA groups were injected with fluorescein isothiocyanate (FITC)-labeled CTS, GA-CTS or GCGA nanoparticles, respectively. We weighed the rats, injected the drugs, then killed the rats 30 minutes later. Liver, spleen, kidney, lung, muscle, and heart tissues were immediately sampled and frozen in 10 µm thick sections. Sections were fixed in 4% paraformaldehyde, stained with Hoechst 33258 for 5 minutes, washed with phosphate buffered saline (PBS) three times, and observed under confocal microscopy to compare the distribution of green fluorescence between the different groups. 
Cytotoxicity of GCGA/5-FU nanoparticles

Data analysis
All data are expressed as mean ± standard deviation (SD). One-way analysis of variance and the least significant difference test were used for comparisons between groups. Kaplan-Meier survival plots were used for survival analysis. A P-value ,0.05 was considered significant.
Results
sustained release property of the GCGA/5-FU nanoparticles
We synthesized successfully the liver/tumor-targeting GCGA/5-FU nanoparticles ( Figure 1A ), which had a mean particle size of 239.9 nm, a polydispersity index of 0.040, a zeta potential of +21.2 mV (Figure 1B) , and a drug loading of 3.90%.
We conducted in vitro experiments to investigate the 5-FU releasing characteristics of the GCGA/5-FU nanoparticles. The drug-release curve indicated that when 5-FU concentration was between 0.1 and 20 mg/L, it had a good linear relationship with the 5-FU peak, and the regression equation was: y = 2.5721x + 0.6851 (r = 0.9956).
(3) Figure 1C shows that the 1-hour cumulative release rate of 5-FU reached 95.67% in vitro. The release of GCGA/5-FU could be divided into five phases: 1) the small burst release phase (0-20 minutes), with a cumulative release rate of 4.9% at 20 minutes; 2) the gentle release phase (20-220 minutes), with a cumulative release rate of 4.9%-7.2% (2.3% increment in cumulative release rate); 3) the second burst release phase (220-280 minutes), with a cumulative release rate of 7.2%-28.5% (21.3% increment in cumulative release rate); 4) the steady release phase (0.2-6 days), with a cumulative release rate of 28.5%-89.1% (60.6% increment in cumulative release rate); and 5) the slow release phase (6-10 days), with a cumulative release rate of 89.1%-96.8% (7.7% increment in cumulative release rate). 
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In vivo distribution of GCGA/5-FU nanoparticles
Previous in vitro studies confirmed that GCGA could target both liver and hepatoma cells, and our study aimed to investigate whether GCGA can redistribute drugs in vivo. Figure 2A shows that the liver had the highest 5-FU concentration among investigated tissues, and that the GCGA/5-FU nanoparticles were most concentrated in the liver, followed by GA-CTS/5-FU, CTS/5-FU, and 5-FU. The liver concentration of 5-FU in the GCGA/5-FU group was 1.65, 2.35, and 2.75 times of the GA-CTS/5-FU, CTS/5-FU, and 5-FU groups, respectively. However, 5-FU concentration in lung, kidney, heart, brain, and muscle tissues exhibited a reversed trend, with the 5-FU groups having the highest 5-FU concentrations, followed by the CTS/5-FU, GA-CTS/5-FU, and GCGA/5-FU groups. Confocal microscopy demonstrated that all three groups showed green fluorescence in the kidneys; the CTS nanoparticles had the highest fluorescence signal, followed by the mono-ligand modified GC-CTS nanoparticles and the dualligand modified GCGA nanoparticles ( Figure 2B ). This trend was also observed in spleen, lung, heart, brain, and muscle tissues. However, a reverse trend was observed in the liver, with the GCGA group having the highest fluorescence signal, followed by the GA-CTS and CTS groups.
Inhibitory effects of GCGA/5-FU nanoparticles in tumor cells are dose and time dependent, and specifically target hepatoma cells The GCGA/5-FU nanoparticles had the highest inhibitory rate in SMMC-7221 cells, followed by the GA-CTS/5-FU nanoparticles. These results suggested that the GCGA/5-FA nanoparticles had significant hepatic tumor-targeting properties; dual-ligand modified nanoparticles had higher inhibitory effects on tumor cells than mono-ligand modified nanoparticles. Nontargeted nanoparticles had a significantly reduced inhibitory effect on tumors compared with 5-FU. Figure 3D shows that the GCGA/5-FU nanoparticles had the highest inhibitory rate in SMMC-7721 cells, followed by the GA-CTS/5-FU nanoparticles. At 1-5 days, 5-FU had a significantly higher inhibitory rate in SW480 and SMMC-7721 cells than GCGA/5-FU (in SW480), GA-CTS/5-FU (in SW480), CTS/5-FU (in SW480), and CTS/5-FU (in SMMC-7721). However, at 6-10 days, the inhibitory rate of 5-FU showed a plateau phase, while nanoparticles showed drastically increased inhibitory rates, which were significantly higher than 5-FU, due to the slow release of the drug. Results suggested that 5-FU from nontargeting nanoparticles could be released slowly, and would not show a plateau phase, indicating that the nontargeting nanoparticles could significantly prolong the efficacy of 5-FU.
GCGA/5-FU nanoparticles enhanced the toxicity in drug-resistant hepatoma cells
In order to study the toxicity of GCGA/5-FU nanoparticles in drug-resistant hepatoma cells, we successfully established a hepatoma cell line with moderate drug resistance. We used 5-FU to test the resistance of normal and resistant SMMC-7221 cells, and the IC 50 for the two cell lines was 6.76 mg/L and 32.34 mg/L, respectively. The RI was calculated as 8.60, indicating that the resistant SMMC-7221 cell line was moderately drug-resistant (Table 1 ). Figure 3E shows that the inhibition of resistant hepatoma cells increased with drug concentration. Under the same drug concentration, GCGA/5-FU had the highest tumor inhibitory rate, followed by GA-CTS/5-FU and 5-FU (all P,0.01). Figure 3F shows that under the same drug concentration, the inhibitory rate of each group increased with time. At the same time point, GCGA/5-FU nanoparticles had the highest inhibitory rate, followed by GA-CTS/5-FU and 5-FU (all P,0.01). These results suggested that GCGA/5-FU nanoparticles exhibited an anti-drug resistance potential, since it had a strong inhibitory effect in drug-resistant hepatoma cells.
GCGA/5-FU nanoparticles inhibited mice live tumor growth and improved mice survival
Ten days after drug injection, mice were killed for tumor tissue sampling and weighing ( Figure 4A ). The mice in the GCGA/5-FU group had the lowest tumor weight, followed by the GA-CTS/5-FU, CTS/5-FU, and 5-FU groups, and the control had the highest tumor weight (all P,0.05). There were no significant differences between the control and GCGA groups (P.0.05). Figure 4B shows that the highest cell density, cell proliferation, and division are obvious in control group and GCGA group, and there is the decreasing tendency from the 5-FU, CTS/5-FU, GA-CTS/5-FU, and GCGA/5-FU groups in turn; the tumor cell necrosis and fibrosis demonstrated opposite trends, and the control and GCGA group presented less necrosis and fibrosis, while there was obvious fibrosis in the GCGA/5-FU group.
After orthotopic liver transplantation, mice were randomly assigned to four groups (n=13), and were treated as described before. Survival analysis was performed using Kaplan-Meier curves ( Figure 4C Mice in the GA-CTS/5-FU group started to die 22 days after model establishment, and were all dead on day 44, showing a median survival time of 37 days. Finally, mice in the GCGA/5-FU group started to die 25 days after model establishment, and were all dead on day 58, showing a median survival time of 45 days. The survival time of mice in the GCGA/5-FU group was the longest (P,0.01). These results suggested that the therapeutic effects of liver-targeting dual-ligand modified nanoparticles significantly surpassed the efficacy of monoligand modified nanoparticles. However, the mono modified nanoparticles were still better than nonliver-targeting nanoparticles. Results indicated that nanoparticles could improve treatment outcomes and prolong survival time, and that the liver-targeting dual modified nanoparticles could most significantly improve drug efficacy and prolong survival.
Discussion
Nanoparticle size and drug loading are two important parameters for a drug delivery system. The pore size of normal vascular endothelial cells is about 2 nm, and the pore size of postcapillary venules is about 6 nm. Liver endothelial cells have pore sizes ranging from 106 to 175 nm, while hepatoma cells have pore sizes from 380 to 580 nm. [22] [23] [24] An 
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Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles ideal nanoparticle size should be larger than the largest pore size of normal liver cells and smaller than the smallest pore size of hepatoma cells. Thus, the nanoparticle size should be between 175 and 380 nm. Drug loading is another important parameter for a drug delivery system. The more drugs a nanoparticle can carry, the higher drug loading it will possess. Thus, many studies have been done to find nanoparticles with high drug loading through rational experimental design and optimization. In this study, GCGA/5-FU nanoparticles had a mean particle size of 239.9 nm, a polydispersity index of 0.040, a zeta potential of +21.2 mV (Figure 1B) , and a drug loading of 3.90%, and we obtained optimized nanoparticles with relatively small particle size and high drug loading.
We used simulated body fluid to investigate the releasing pattern of GCGA/5-FU nanoparticles. Figure 1C shows that in vitro release of GCGA/5-FU could be divided into five phases. 1) The small burst release phase (0-20 minutes, with a cumulative release rate of 4.9% at 20 minutes) can be explained by residual 5-FU during nanoparticle preparation.
2) The gentle release phase (20-220 minutes, with a cumulative release rate of 4.9%-7.2%, 2.3% increment in cumulative release rate), which brings the gentle release of drug mainly through diffusion from the nanoparticles.
3) The second burst release phase (220-280 minutes, with a cumulative release rate of 7.2%-28.5%, 21.3% increment in cumulative release rate) comes after the gentle release phase. Figure 1D shows that the GCGA/5-FU nanoparticles had a 3-layer structure, with the inner layer composed of hydrophobic GA and insoluble CTS derivatives that could only attract a small amount of hydrophilic 5-FU. However, the outer layer is composed of hydrophilic lactobionate and CTS branches that can coat the drug and retain it in the matrix. Thus, the burst of drug in the third phase may be due to the degradation of the particle outer layer, leading to the breaking of hydrogen bonds between 5-FU and polymers, and the drugs retained in the outer layer are then rapidly dissociated and released. 4) The steady release phase (0.2-6 days, with a cumulative release rate of 28.5%-89.1%, 60.6% increment in cumulative release rate) that follows the second burst release phase could be explained by the continuous release of drugs from the degraded insoluble or hydrophobic materials. 5) The final stage, the slow release phase (6-10 days, with a cumulative release rate of 89.1%-96.8%, 7.7% increment in cumulative release rate), could be attributed to the slow release of 5-FU from the residual nanoparticles. Our results suggested that the GCGA/5-FU showed significant slow release properties.
Previous studies confirmed that GCGA nanoparticles had in vitro liver-targeting properties. 20 Figure 2A shows that GCGA/5-FU nanoparticles had the highest liver concentration, which was 1.65, 2.35, and 2.75 times the concentrations of the GA-CTS/5-FU, CTS/5-FU, and 5-FU nanoparticles, respectively. However, the concentration of 5-FU in lung, spleen, heart, brain, and muscle tissues decreased from the 5-FU, CTS/5-FU, and GA-CTS/5-FU groups to the GCGA/5-FU group, and this trend was consistent with the results from confocal microscopy, as shown in Figure 2B . The results can be explained, as the dual-ligand modified GCGA/5-FU nanoparticles had higher liver targeting properties than the mono-ligand modified GA-CTS and nonligand modified CTS nanoparticles. In addition, results suggested that ligand modified GA-CTS and GCGA particles both had good liver-targeting properties, but that GCGA particles had higher liver specificity. This was because under pathological conditions, the galactose receptor binding activity would decline, 11 and the GA receptor had higher expression in cancer cells. 9 Since the GCGA nanoparticles are modified with the ligands of both target receptors, they possessed a stronger liver-targeting property compared with other monoligand modified nanoparticles.
In terms of tumor-targeting properties of the GCGA/5-FU nanoparticles, our study found that with increases in 5-FU concentrations, the inhibitory effect on SW480 and SMMC-7721 also significantly increased. At 24, 48, and 72 hours, the liver-targeting nanoparticles had the highest 
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Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles endocytosis, resulting in nontargeted therapy by the CTS/5-FU nanoparticles in SW480 and SMMC-7721 cells. Also, due to the slow release of 5-FU, the concentration of 5-FU remained low in the tumor cells, and explained the low inhibitory rate of the GCGA and GA-CTS nanoparticles in tumor cells. Figure 3D showed that at 1-5 days, GCGA/5-FU and GA-CTS/5-FU nanoparticles had the highest inhibitory rate in SMMC-7721 tumor cells, and that the inhibitory effect of 5-FU in SW480 and SMMC-7721 cells was significantly higher than GCGA/5-FU in SW480, GA-CTS/5-FU in SW480, CTS/5-FU in SW480, and CTS/5-FU in SMMC-7721 cells. At 6-10 days, the inhibitory rate of the GCGA/5-FU and GA-CTS nanoparticles in SMMC-721 cells still remained the highest, while the inhibitory rate of 5-FU in SW480 and SMMC-7721 cells showed a plateau phase, which may due to the short effective time of 5-FU. However, since 5-FU can be slowly released from the GCGA/5-FU, GA-CTS/5-FU, and CTS/5-FU nanoparticles, the inhibitory rates of these nanoparticles gradually increased instead of showing a plateau phase. Thus, the nanoparticles could significantly prolong the efficacy of 5-FU in tumor cells.
We established a 5-FU resistant SMMC-7721 cell line to investigate the anti-drug resistance potential of the GCGA/5-FU nanoparticles. Generally, cell lines with low, moderate, and high resistance show a drug RI ,5, between 5 and 15, and .15, respectively. 25 The 5-FU resistant SMMC-7721 cell line established in this study was a moderate resistant cell line, since it had a RI of 8.60. Our study found that GCGA/5-FU could significantly inhibit the proliferation of 5-FU resistant SMMC-7721 cells in vitro, and such inhibition was obviously more effective than when using 5-FU alone. These results indicated that the SMMC-7721 cells are resistant to free 5-FU. The metabolite of 5-FU, 5-fluorouracil oligodeoxynucleotide, inhibits thymidylate synthase synthesis, thus preventing the methylation of dUMP to dTMP, blocking DNA synthesis. Water and lipid solubility of 5-FU are very low due to its unique structure, and resistance to 5-FU can be attributed to cell membrane, enzyme, or genetic abnormalities. [26] [27] [28] GCGA induced endocytosis of 5-FU by interacting with the ASGP-R and GA receptors on hepatoma cells surface, and the GCGA nanoparticles had significantly higher anti-drug resistance potential due to a different resistance mechanism from the mechanism against free 5-FU.
In order to evaluate the tumor suppressing potential of GCGA/5-FU nanoparticles in vivo, we treated orthotopic liver transplantation mouse models with GCGA/5-FU for 5 days, and tumor weight was measured. Figure 4A shows that mice injected with GCGA/5-FU had the lowest tumor weight, which was significantly lower than in mice injected with mono-targeting GA-CTS/5-FU and nonliver-targeting CTS/5-FU nanoparticles. This indicated that when compared with the GA-CTS/5-FU and CTS/5-FU nanoparticles, the GCGA nanoparticles induced a more important endocytosis of 5-FU, resulting in higher 5-FU concentration and a lower tumor weight in GCGA/5-FU injected mice. In terms of toxicity, 5-FU caused liver damage and blood cell suppression, while GCGA nanoparticles attenuated these side effects to some extent. Survival analysis suggested that mice injected with GCGA/5-FU nanoparticles had the longest survival time (45 days), while mice injected with GA-CTS/5-FU and CTS/5-FU nanoparticles had a survival time of 37 days and 30 days, respectively, and mice injected with 5-FU had the shortest (24 day) survival time. Results indicated that dual-targeting nanoparticles could mediate more stable endocytosis of 5-FU compared with mono-targeting nanoparticles; and nontargeting nanomaterial showed higher tumor inhibiting capacity than free 5-FU because of its slow release properties.
In conclusion, we synthesized successfully the liver/ tumor-targeting GCGA/5-FU nanoparticles, which slowly released their 5-FU. The in vitro inhibitory effects of GCGA/5-FU nanoparticles on liver tumor were time and dose dependent. GCGA/5-FU nanoparticles significantly reduced the resistance of hepatoma cells to 5-FU, significantly suppressed tumor growth in a liver transplantation mouse model, and prolonged mouse survival time.
